|
No S-ICU-DD
|
S-ICU-DD
|
p
|
---|
No weakness
|
ICU-AW
|
No weakness
|
ICU-AW
|
---|
N
|
36 (31%)
|
32 (28%)
|
14 (12%)
|
34 (29%)
| |
---|
Demographic data
|
Men, n (%)
|
27 (75)
|
19 (59)
|
7 (58)
|
24 (71)
|
0.522
|
Age, years
|
58 (40–55)
|
56 (50–65)
|
70 (50–78)*
|
64 (56–75)*#
|
0.009
|
Body mass index, kg/m2
|
24 (21–27)
|
23 (21–26)
|
24 (20–33)
|
25 (22–29)
|
0.302
|
Medical conditions
|
COPD, n (%)
|
7 (19)
|
0 (0)*
|
3 (21)#
|
7 (21) #
|
0.049
|
Heart failure, n (%)
|
7 (19)
|
2 (6)
|
2 (14)
|
6 (18)
|
0.453
|
Reason for ICU admission
|
Shock
|
11 (33)
|
10 (31)
|
3 (21)
|
13 (38)
|
0.793
|
Coma
|
13 (39)
|
5 (19)
|
3 (21)
|
6 (18)
|
0.186
|
Acute respiratory failure
|
12 (33)
|
17 (53)
|
8 (57)
|
15 (44)
|
0.387
|
On admission
|
SOFA
|
4 (3–5)
|
7 (4–10)*
|
6 (5–8)*
|
8 (5–13)*
|
< 0.0001
|
Sepsis, n (%)
|
24 (67)
|
23 (72)
|
7 (58)
|
23 (68)
|
0.830
|
At inclusion
|
MV prior to inclusion, days
|
3 (1–5)
|
4 (4–9)
|
5 (1–7)*
|
9 (5–15)*†
|
< 0.0001
|
Medication exposure
| | | | | |
Neuromuscular blocker, n (%)
|
4 (11)
|
13 (41)*
|
4 (28)
|
17 (50)*
|
0.017
|
Corticosteroids, n (%)
|
1 (3)
|
3 (9)
|
4 (28)*
|
1 (3)†
|
< 0.0001
|
Norepinephrine, n (%)
|
9 (25)
|
21 (66)*
|
3 (21)#
|
30 (88)*†
|
< 0.0001
|
Midazolam, n (%)
|
11 (31)
|
16 (50)
|
5 (36)
|
13 (38)
|
0.346
|
Propofol (%)
|
23 (64)
|
5 (19)*
|
7 (50)#
|
5 (15)*†
|
< 0.0001
|
Sufentanil, n (%)
|
16 (44)
|
21 (66)
|
7 (50)
|
31 (91)* †#
|
0.001
|
Muscle assessment
|
Ptr,stim, cmH2O
|
10.9 (7.9–15.3)
|
11.0 (9.0–14.0)
|
5.0 (4.1–6.3)*#
|
3.5 (2.4–6.3)*#
|
< 0.0001
|
MRC score
|
56 (51–59)
|
35 (23–43)*
|
55 (51–57)#
|
33 (24–40)*†
|
< 0.0001
|
- Data are expressed as median (interquartile range) or n (%)
- COPD chronic obstructive pulmonary disease, SOFA Sequential Organ Failure Assessment, MV mechanical ventilation, Ptr,stim endotracheal tube pressure induced by bilateral phrenic nerve stimulation during airway occlusion, MRC Medical Research Council
- *vs. No S-ICU-DD–No ICU-AW
- #vs. No S-ICU-DD–ICU-AW
- †vs. S-ICU-DD–No ICU-AW